Ventral Striatal Dopamine Release in Response to Smoking a Regular vs a Denicotinized Cigarette

Arthur L Brody^{*,1,2}, Mark A Mandelkern^{2,3}, Richard E Olmstead², Zoe Allen-Martinez², David Scheibal², Anna L Abrams², Matthew R Costello^{1,2}, Judah Farahi², Sanjaya Saxena⁴, John Monterosso¹ and Edythe D London^{1,5}

¹UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA, USA; ²Greater Los Angeles VA Healthcare System Positron Emission Tomography Center, Los Angeles, CA, USA; ³UCI Department of Physics, Irvine, CA, USA; ⁴UCSD Department of Psychiatry, San Diego, CA, USA; ⁵UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, USA

Prior studies have demonstrated that both nicotine administration and cigarette smoking lead to dopamine (DA) release in the ventral striatum/nucleus accumbens. In tobacco-dependent individuals, smoking denicotinized cigarettes leads to reduced craving, but less pleasure, than smoking regular cigarettes. Using denicotinized cigarettes and ¹¹C-raclopride positron emission tomography (PET) scanning, we sought to determine if nicotine is necessary for smoking-induced DA release. Sixty-two tobacco-dependent smokers underwent ¹¹C-raclopride PET scanning, during which they smoked either a regular or denicotinized cigarette (double-blind). Change in ¹¹C-raclopride binding potential (BP) in the ventral striatum from before to after smoking was determined as an indirect measure of DA release. Cigarette craving, anxiety, and mood were monitored during scanning. Smoking a regular cigarette resulted in a significantly greater mean reduction in ventral striatal ¹¹C-raclopride BP than smoking a denicotinized cigarette. Although both groups had reductions in craving and anxiety with smoking, the regular cigarette group had a greater improvement in mood. For the total group, change in BP correlated inversely with change in mood, indicating that greater smoking-induced DA release was associated with more smoking-related mood improvement. Thus, nicotine delivered through cigarette smoking appears to be important for ventral striatal DA release. Study findings also suggest that mood improvement from smoking is specifically related to ventral striatal DA release.

Neuropsychopharmacology (2009) **34**, 282–289; doi:10.1038/npp.2008.87; published online 18 June 2008

Keywords: dopamine; nicotine; tobacco; ventral striatum; positron emission tomography; ¹¹C-raclopride

INTRODUCTION

Many research groups have demonstrated that nicotine administration or cigarette smoking results in dopamine (DA) release in the ventral striatum/nucleus accumbens (VST/NAc). In studies of rodents, nicotine-induced DA release in the VST/NAc was shown using microdialysis (Di Chiara and Imperato, 1988; Damsma *et al*, 1989; Pontieri *et al*, 1996; Sziraki *et al*, 2001), whereas nicotine-induced DA release was disrupted by lesioning of dopaminergic neurons prior to nicotine administration (Corrigall *et al*, 1992). In non-human primates, DA release in response to intravenous nicotine administration has been demonstrated (indirectly) by displacement of ¹¹C-raclopride (a ligand that binds to D2/D3 DA receptors) during positron emission tomography (PET) scanning (Dewey *et al*, 1999; Marenco *et al*, 2004). Similarly, studies of human smokers have

demonstrated DA release in response to cigarette smoking (Brody *et al*, 2004, 2006; Scott *et al*, 2007) and nicotine gum administration (Takahashi *et al*, 2008) using ¹¹C-raclopride and PET, though not all studies using these (and similar) methods have shown ¹¹C-raclopride displacement (Tsukada *et al*, 2002; Barrett *et al*, 2004; Montgomery *et al*, 2007). Both nicotine administration (in doses comparable to human cigarette smoking) (Cumming *et al*, 2003; Marenco *et al*, 2004; Takahashi *et al*, 2008) and cigarette smoking itself (Brody *et al*, 2004, 2006; Scott *et al*, 2007) result in DA release in the range of 5–10%, indicating that nicotine intake is an important factor in DA release from smoking. Significant associations between DA release (as measured by ¹¹C-raclopride displacement) and behavioral responses to smoking, such as reduction in craving (Brody *et al*, 2004, 2006) and enhancement of pleasure (Barrett *et al*, 2004; Montgomery *et al*, 2007), have also been demonstrated in human smokers.

In prior research, smoking denicotinized cigarettes has been compared to smoking regular cigarettes, to examine the effect of the presence or absence of nicotine on tobacco-related symptoms. In tobacco-dependent smokers, smoking denicotinized cigarettes has been found to result in a degree

*Correspondence: Dr AL Brody, UCLA Department of Psychiatry & Biobehavioral Sciences, 300 UCLA Medical Plaza, Suite 2200, Los Angeles, CA 90095, USA, Tel: +310 268 4778, Fax: +310 206 2802, E-mail: abrody@ucla.edu

Received 6 March 2008; revised 9 May 2008; accepted 10 May 2008

of withdrawal relief that is similar to smoking regular cigarettes (Pickworth *et al*, 1999; Buchhalter *et al*, 2001; Dallery *et al*, 2003; Donny *et al*, 2007); however, denicotinized cigarettes provide less satisfaction (Butschky *et al*, 1995; Gross *et al*, 1997), reward (Naqvi and Bechara, 2005; Donny *et al*, 2007), and anxiety reduction (Pomerleau *et al*, 1984; Buckley *et al*, 2007) than regular cigarettes. Denicotinized cigarettes also do not elevate heart rate like regular cigarettes (Butschky *et al*, 1995; Pickworth *et al*, 1999; Schuh *et al*, 2001; Buchhalter *et al*, 2001), but both cigarette types increase skin conductance responses (Naqvi and Bechara, 2006). Furthermore, a recent study directly demonstrated that the airway sensation from nicotized cigarette puffs were more rewarding than such sensations from denicotinized cigarette puffs (though both cigarette types produced greater reward than unlit puffs) (Naqvi and Bechara, 2005). Taken together, these studies indicate that sensory factors associated with smoking are important for relief of withdrawal, but that nicotine may be necessary for the rewarding properties of smoking.

Using denicotinized (and regular) cigarettes and ^{11}C -raclopride PET scanning, the primary goal of the study presented here was to determine if nicotine is necessary for smoking-induced DA release. Given the extensive scientific literature linking reward/pleasure with DA release (Koob, 1992; Leshner and Koob, 1999) and the aforementioned studies of denicotinized cigarettes indicating less of a rewarding effect from these cigarettes, we hypothesized that smoking a denicotinized cigarette during scanning would result in less DA release than smoking a regular cigarette. Given that prior studies demonstrate associations between DA release and hedonic responses and craving reduction with smoking, and that smoking reduces anxiety in the presence of a stressor (Jarvik *et al*, 1989) and when a distractor is present (Kassel and Shiffman, 1997), we also sought to examine associations between DA release and change in these symptoms with smoking.

METHODS

Research Participants

Two hundred and forty-three potential research participants were screened during a telephone interview, in which medical, psychiatric, and substance abuse histories were obtained without personal identifiers. Qualified participants who wished to participate received a complete description of the study in person and gave written informed consent, using forms approved by the local IRB. Participants were then evaluated further using screening questions from the Structured Clinical Interview for DSM-IV to verify eligibility (First *et al*, 1995). Inclusion/exclusion criteria were the same as in our previous reports (Brody *et al*, 2004, 2006), with the central inclusion criteria being DSM-IV nicotine dependence and smoking 10–40 cigarettes per day and exclusion criteria being any history of an Axis I psychiatric or substance abuse/dependence diagnosis other than nicotine dependence, current use of medications or medical conditions that might affect brain function, and pregnancy. Participants were all treatment seeking and were either enrolled in a larger smoking cessation treatment study or offered open-label treatment following study participation.

Experimental Design

Sixty-two otherwise healthy adult (21–65 years of age) cigarette smokers completed the following study. Participants underwent bolus-plus-continuous-infusion ^{11}C -raclopride PET scanning, during which they smoked either a regular or denicotinized cigarette (double-blind). Demographic and other clinical variables were collected at baseline, and symptoms of tobacco withdrawal were monitored during the scanning session. A structural magnetic resonance imaging (MRI) scan was also obtained within 1 week of the PET session.

Demographic and Rating Scale Measures

Demographic and rating scale measures were obtained immediately prior to PET scanning. Demographic data included age, sex, number of cigarettes per day, number of years smoking, and highest level of education. Rating scale data included the Fagerström Test for Nicotine Dependence (FTND) (Fagerström, 1978; Heatherton *et al*, 1991), Hamilton Depression (HAM-D) (Hamilton, 1967) and Anxiety (HAM-A) (Hamilton, 1969) rating scales, and the Shiffman–Jarvik Withdrawal Scale (Shiffman and Jarvik, 1976). Exhaled carbon monoxide (CO) levels were also obtained prior to PET scanning using a MicroSmokerlyzer (Bedfont Scientific Ltd, Kent, UK) as an estimate of recent smoking levels.

During the PET session, the Urge to Smoke (UTS) Scale for measuring craving (Jarvik *et al*, 2000), state anxiety questions from the Spielberger State-Trait Anxiety Index (Spielberger, 1983), and an analog scale for mood rating (from ‘sad’ to ‘happy’) (Wild *et al*, 2001; Bowen *et al*, 2006; Mitterschiffthaler *et al*, 2007) were administered immediately before and after smoking.

PET and MRI Scanning

Positron emission tomography and MRI scanning sessions followed the same general protocol as in our previous reports (Brody *et al*, 2004, 2006). PET sessions were performed using a bolus plus continuous infusion of ^{11}C -raclopride. Participants were instructed to smoke as per their usual habit on the morning of the PET session and to smoke a cigarette immediately prior to testing, which began at noon. Between noon and 1345 hours, participants were interviewed and filled out rating scale questionnaires as described above. At 1345 hours, each participant had a 20-gauge intravenous catheter placed and then was positioned on the PET scanning bed (for acquisition of planes parallel to the orbitomeatal line). Scanning began at 1410 hours with a slow bolus injection of 5 mCi ^{11}C -raclopride in 20 ml normal saline over a 60-s period, followed by continuous infusion of the tracer (5 mCi, corrected for decay) for the remainder of the testing session. This bolus-plus-continuous-infusion method was performed as described in prior studies (Carson *et al*, 1997; Ito *et al*, 1998; Brody *et al*, 2006). Brain scans were acquired continuously for the next 50 min.

At 1500 hours, participants were removed from the scanner with the infusion still running and had a 10-min break in an outdoor area adjacent to the PET scanning room, at which time they smoked either a regular or

denicotinized cigarette (described below). A 3-h period of abstinence prior to the smoke break in scanning was chosen based on the finding that craving starts to peak at this time in smokers (Schuh and Stitzer, 1995), though it is acknowledged that DA release may be different if smokers are cigarette-deprived for longer periods of time. After the break, participants were quickly repositioned (<1 min) in the scanner using a preplaced mark on their forehead and a laser light from the scanner. Scanning then resumed for 30 min more.

Positron emission tomography scans were acquired with a GE Advance NXi PET tomograph (General Electronic Medical Systems, Milwaukee, WI) with 35 slices in 3-dimensional mode. ^{11}C -raclopride was prepared by an established procedure (Farde *et al*, 1986; Ehrin *et al*, 1987). PET scans were acquired as 10 prebreak and six postbreak 5-min frames. Attenuation correction scanning for both emission scans was performed using a 5-min transmission scan obtained with the germanium rotating rod source built into the GE scanner at the end of the scanning session.

An MRI scan of the brain was obtained within 1 week of the PET session with the following specifications: three-dimensional Fourier transform spoiled gradient-recalled acquisition with TR = 30 ms, TE = 7 ms, 30° angle, two acquisitions, 256 × 192 view matrix. The acquired volume was reconstructed as 90 contiguous, 1.5-mm thick, transaxial slices.

Cigarette Smoking during the Break in Scanning

During the break in scanning, subjects smoked either one of their own cigarettes (mean 1.0 ± 0.03 mg nicotine, 14.2 ± 0.5 mg tar; $n = 46$) or a standard denicotinized cigarette (0.05 mg nicotine, 10 mg tar; Quest 3 brand; $n = 16$). Three-fourths of the participants were assigned to the regular cigarette group because this study was part of a larger treatment study that examined responses to regular cigarettes before and after treatment, and only those who smoked a regular cigarette were eligible for the larger study. To maintain a blind, all subjects gave one of their cigarettes to a research assistant who de-identified it by covering any brand markings. This de-identified regular brand cigarette or a de-identified denicotinized cigarette was then given to the study investigator (ALB, REO, or ZAM) who gave it to the participant to smoke during the break in scanning. Participants were observed continuously during the break. For the regular cigarette condition, subjects smoked one of the following cigarettes: Marlboro Regular ($n = 9$), Marlboro 100 ($n = 2$), Marlboro Light ($n = 1$), Camel Regular ($n = 6$), Camel Light ($n = 3$), Kool Regular ($n = 3$), Newport Regular ($n = 6$), Newport 100 ($n = 5$), Parliament Light ($n = 9$), or Benson and Hedges Regular ($n = 2$). Eleven of the cigarettes smoked for the regular cigarette condition were menthol cigarettes, whereas the denicotinized cigarettes were not menthol cigarettes.

To monitor smoking topography during scanning, cigarettes were smoked through a Clinical Research Support System device (Plowshare, Baltimore, MD). Although all standard recordings were obtained with this device, the primary measure of interest was total puff volume of the cigarette (ml), which indicated the amount of each cigarette that was smoked.

PET Image Analysis

PET-to-MRI coregistration was performed using an automated image registration method (Woods *et al*, 1993) within MEDx 3.3 (Sensor Systems Inc., Sterling, VA). Prebreak (0–50 min) and postbreak (60–90 min) scans were coregistered to the MRI separately, and the individual 5-min time frames were coregistered to MRI scans using the transformation matrix parameters from the coregistration of the summed images.

Regions of interest (ROIs) were drawn on MRI and transferred onto the coregistered PET scan frames. ROI placement on each frame was verified by visual inspection by the region drawers (MRC and DS) and the PI. The ROI value used for statistical analysis was the volume-weighted decay-corrected mean of the left and right ventral caudate (VCD) ROIs (including NAc), consisting of three slices each, resulting in a single value for each 5-min frame of PET scanning (Brody *et al*, 2006). The cerebellum was drawn as a reference region. These regions were similar to those drawn in prior ^{11}C -raclopride PET studies (Mawlawi *et al*, 2001; Martinez *et al*, 2003). Binding potential (BP) for VCD/NAc was calculated using the simplified reference tissue model (Lammertsma and Hume, 1996), with $\text{BP} = B'_{\text{max}}/K_d = C_{\text{VCD/NAc}}/C_{\text{cerebellum}} - 1$, where C is radioligand concentration. BP was determined for each 5-min PET frame, and mean BP values were compared between the frames before (40–50 min) and after (60–90 min) the break in scanning. These time frames are almost identical to those recommended as optimal for maximizing signal-to-noise ratio with the ^{11}C -raclopride bolus-plus-continuous-infusion method (Watabe *et al*, 2000; Mawlawi *et al*, 2001). This method assumes 40 min for the radiotracer to reach an approximate steady state (Ito *et al*, 1998; Watabe *et al*, 2000; Mawlawi *et al*, 2001). It also assumes that intrasynaptic DA concentration will remain elevated throughout the 30-min postsmoking scan, as indicated by animal microdialysis and imaging studies cited above.

The single PET data variable for this study was percent change in BP from before to after smoking, defined as $100 \times (\text{BP}_{\text{after smoking}} - \text{BP}_{\text{before smoking}}) / \text{BP}_{\text{before smoking}}$. A single BP measure was used here, based on prior reports demonstrating nearly identical BP changes for the left and right VCD/NAc (Brody *et al*, 2004, 2006), to minimize the risk of type I error.

Statistical Analyses

Demographic and rating scale data means ($\pm$ SEMs) were determined for the study groups. To verify baseline similarities in demographics between groups, unpaired Student's t -tests and a χ^2 test (for gender) were performed for these variables. To determine similarities and differences in clinical responses to smoking the two cigarette types, unpaired Student's t -tests were performed between groups for changes in the three withdrawal symptom measures (craving/UTS, anxiety/Spielberger State-Trait Anxiety Index (STAI), and mood analog scale scores) from before to after smoking. To further characterize pre- to postsmoking changes in withdrawal symptoms, within-group paired t -tests and examinations of means were also performed.

For the PET data, changes in BP were compared between groups with an ANCOVA, with percent change in BP as the dependent measure, group (regular vs denicotinized cigarette) as the between-subject factor, and age, gender, and total puff volume as covariates. Even though the groups did not have significant differences in these covariates (see below), these variables were included in the analysis, based on prior reports linking them with differences in DA system function (Wang *et al*, 1995; Pohjalainen *et al*, 1998; Kaasinen *et al*, 2000; Staley *et al*, 2001).

For the total group, correlation coefficients (controlling for group) were determined between percent change in BP and percent change in craving (UTS), state anxiety (STAI), and mood analog scores, to determine relationships between DA concentration change and effects of smoking on withdrawal symptoms. All statistical tests were performed with SPSS version 15.0 (SPSS, Chicago, IL).

RESULTS

Clinical Results

The total subject sample was middle-aged (40.5 ± 1.5 years old), mostly male (67.7%), smoked moderately (24.2 ± 0.9 cigarettes/day) and for many years (22.5 ± 1.5), was moderately nicotine-dependent (FTND scores— 6.4 ± 0.2), and had moderate CO levels prior to the scanning session (17.0 ± 1.1 p.p.m.). The groups assigned to smoking either a regular or a denicotinized cigarette did not differ significantly in any of these variables (Table 1) or on any of the subscales from the Shiffman–Jarvik Withdrawal scale (all unpaired Student's *t*-tests, NS).

The groups also did not differ in smoking topography. For the regular and denicotinized cigarette groups, total puff volume (886 ± 44 vs 941 ± 81 ml, respectively), number of puffs (17.3 ± 1.2 vs 19.3 ± 1.8 , respectively), and average

puff volume (57.3 ± 2.7 vs 52.6 ± 4.5 ml) were similar between groups (all unpaired Student's *t*-tests, NS).

From before to after smoking during scanning, the two groups did not differ significantly in craving or anxiety alleviation (both unpaired Student's *t*-tests, NS), but did differ in mood improvement. For craving, both groups had significant within-group reductions in craving/UTS score ($-76.0 (\pm 3.5)\%$ for the regular cigarette group, paired Student's *t*-test, $p < 0.0001$ and $-71.8 (\pm 6.9)\%$ for the denicotinized cigarette group, paired Student's *t*-test, $p < 0.0001$), indicating that craving was reduced significantly with both cigarette types. Similarly, both groups had comparable reductions in STAI anxiety scale scores ($-26.1 (\pm 19.5)\%$ for the regular cigarette group and $-21.7 (\pm 16.3)\%$ for the denicotinized cigarette group). In contrast, the regular cigarette group had significantly more mood improvement ($+15.2 (\pm 6.0)\%$) than the denicotinized cigarette group ($-0.5 (\pm 4.4)\%$) (unpaired Student's *t*-test, $p = 0.04$).

PET Results

The group that smoked regular nicotine-containing cigarettes had a greater mean reduction in ^{11}C -raclopride BP ($-8.4 (\pm 1.5)\%$) than the group that smoked denicotinized cigarettes ($-1.2 (\pm 2.5)\%$) (ANCOVA, d.f. = 1, 57, $F = 6.8$, $p = 0.01$) (Figure 1), indicating that those who smoked regular cigarettes had greater DA release.

For the total group, there was a significant negative correlation between change in ^{11}C -raclopride BP and change in mood scale scores (correlation coefficient, $r = -0.33$, $p = 0.01$) (Figure 2), indicating that greater DA release is associated with more mood improvement. There were no significant correlations between change in ^{11}C -raclopride BP and change in UTS scale scores (correlation coefficient, $r = 0.13$, NS) or STAI anxiety scale score (correlation coefficient, $r = -0.01$, NS).

Table 1 Demographic and Rating Scale Variables

Variable	Total group (n = 62)	Regular nicotine cigarette (n = 46)	De-nicotinized cigarette (n = 16)	p-value (Nic vs De-Nic groups)
Age	40.5 (± 1.5)	41.6 (± 1.7)	37.3 (± 3.4)	NS
Percent female	32.3%	34.8%	25.0%	NS
Cigs/day	24.2 (± 0.9)	24.9 (± 1.0)	22.3 (± 1.6)	NS
Years of smoking	22.5 (± 1.5)	23.5 (± 1.7)	19.8 (± 3.3)	NS
Education (yrs)	13.8 (± 0.2)	13.8 (± 0.3)	13.9 (± 0.3)	NS
FTND	6.4 (± 0.2)	6.4 (± 0.3)	6.4 (± 0.4)	NS
HAM-D	1.8 (± 0.3)	1.5 (± 0.3)	2.4 (± 0.6)	NS
HAM-A	2.0 (± 0.3)	1.7 (± 0.3)	2.6 (± 0.8)	NS
CO level (p.p.m.)	17.0 (± 1.1)	17.5 (± 1.5)	15.3 (± 1.7)	NS
% Change in UTS (craving) with smoking	-74.9 (± 3.1)	-76.0 (± 3.5)	-71.8 (± 6.9)	NS
% Change in STAI with smoking	-25.0 (± 15.0)	-26.1 (± 19.5)	-21.7 (± 16.3)	NS
% Change in Mood with smoking	7.6 (± 5.4)	15.2 (± 6.0)	-0.5 (± 4.4)	0.04

Values are stated as mean ($\pm$ SEM); *p*-values are for unpaired Student's *t*-tests between the groups that smoked either a regular nicotine or a denicotinized cigarette. Cig, cigarette; CO, exhaled carbon monoxide; De-Nic, denicotinized; FTND, Fagerström Test for Nicotine Dependence; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; Mood, mood analog rating scale score; Nic, nicotine; NS, nonsignificant; p.p.m., parts per million; STAI, Spielberger State-Trait Anxiety Index state anxiety questions total score; UTS, Urge to Smoke Scale; yrs, years.

Figure 1 Scatterplot showing percent change in ^{11}C -raclopride binding potential (BP) for the group that smoked a denicotinized cigarette ($-1.2 (\pm 2.5)\%$; $n = 16$) and the group that smoked a regular cigarette ($-8.4 (\pm 1.5)\%$; $n = 46$). The group that smoked a denicotinized cigarette had less of a decrease in ^{11}C -raclopride BP than the group that smoked a regular cigarette, indicating that nicotine inhalation is important for dopamine release.

Figure 2 Scatterplot showing the negative correlation ($r = -0.33$, $p = 0.01$) between percent change in ^{11}C -raclopride binding potential (BP) (an indirect measure of dopamine release) and percent change in mood analog rating scale score for the total group of tobacco-dependent smokers ($n = 62$).

DISCUSSION

In tobacco-dependent smokers, smoking regular vs denicotinized cigarettes resulted in different patterns of both clinical and PET scanning findings. Smoking regular cigarettes resulted in significantly decreased craving and anxiety, improved mood, and DA release, whereas smoking denicotinized cigarettes resulted in decreased craving and anxiety, but no evidence of mood improvement or significant DA release. In addition, for the total group, there was an association between increasing DA release and mood improvement. These findings indicate that nicotine

is necessary for smoking-induced DA release and support prior research demonstrating that denicotinized cigarettes relieve craving (Eid *et al*, 2005; Buchhalter *et al*, 2005), but that regular nicotine-containing cigarettes provide greater withdrawal relief (Pickworth *et al*, 1999; Buchhalter *et al*, 2001; Dallery *et al*, 2003; Donny *et al*, 2007) and more satisfaction (Butschky *et al*, 1995; Gross *et al*, 1997) and reward (Naqvi and Bechara, 2005; Donny *et al*, 2007) (measured here as mood improvement) than denicotinized cigarettes. The central finding of this study (smoking a regular cigarette resulting in greater displacement of ^{11}C -raclopride BP than smoking a denicotinized cigarette) is consistent with animal microdialysis (Imperato *et al*, 1986; Di Chiara and Imperato, 1988; Benwell and Balfour, 1997; Janhunen and Ahtee, 2004) and imaging (Marenco *et al*, 2004; Scott *et al*, 2007; Takahashi *et al*, 2008) studies, which demonstrate the importance of nicotine administration for DA release. As expected, the 8.4% increase in DA concentration found here with smoking a regular cigarette was less than the 20–29% increase found with cocaine (Volkow *et al*, 1999; Park and Park, 2000) or the 19–31% increase found with amphetamine (Carson *et al*, 1997; Hartvig *et al*, 1997; Drevets *et al*, 1999) administration in studies using similar methodology.

The finding of a reduction in craving with smoking a denicotinized cigarette also indicates that factors other than the rewarding effect of ventral striatal DA release are important for craving alleviation. Denicotinized cigarettes likely alleviate craving through either (1) the sensorimotor feel, taste, and smell of cigarettes (including some degree of airway sensory stimulation (Naqvi and Bechara, 2005)), (2) DA release in brain regions not studied here (such as the thalamus, hippocampus, and cerebral cortex (Christian *et al*, 2000; Slifstein *et al*, 2004)), (3) pharmacological effects of the thousands of constituents of tobacco smoke other than nicotine (Green and Rodgman, 1996), or (4) some combination of these factors. To clarify the issue of how denicotinized cigarettes exert their effect, studies of changes in brain activity (either blood flow or glucose metabolism) or other neurotransmitter systems in response to smoking these cigarettes would be informative. Though several groups have examined the smoking of denicotinized cigarettes as a control condition compared to smoking regular cigarettes during functional brain imaging (Rose *et al*, 2003, 2007; Zubieta *et al*, 2005), we are aware of only one study (cited below) that specifically examined the effects of smoking denicotinized cigarettes themselves on brain function.

Although (to our knowledge) no prior functional brain imaging studies have directly reported how denicotinized cigarettes alleviate craving, several functional brain imaging studies of cigarette craving itself (see Brody (2006) for review) point to brain circuitry that might mediate the diminished craving found in response to denicotinized cigarettes. When cigarette smokers are exposed to cigarette-related (compared to neutral) cues, craving is found to correlate with regional glucose metabolism or perfusion in the prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, insula, sensorimotor cortex, and hippocampus (Brody *et al*, 2002; Zubieta *et al*, 2005; Rose *et al*, 2007). Changes in activity in these regions, which mediate brain functions possibly related to craving (eg, working and

episodic memory, repetitive thoughts, arousal and sensorimotor function) could be responsible for the craving reduction seen with denicotinized cigarettes. The effects of smoking denicotinized cigarettes on craving may also be explained by their effect on neurotransmitter systems other than DA, as demonstrated in a recent study showing activation of mu-opioid receptor-mediated neurotransmission in the right anterior cingulate cortex from smoking denicotinized and regular nicotine cigarettes (Scott *et al*, 2007).

As for the other central finding of this study, the association between mood improvement and smoking-induced DA release is consistent with a large body of literature linking DA release with improved mood and pleasure. Most closely related to the present study are reports using ^{11}C -raclopride PET that have linked DA release in the striatum with hedonic responses to cigarette smoking (Barrett *et al*, 2004) and with happiness following nicotine nasal spray administration (Montgomery *et al*, 2007). Similar relationships between DA release and mood improvement or reward have been demonstrated in response to amphetamine administration (Drevets *et al*, 2001; Oswald *et al*, 2005), monetary reward (Pappata *et al*, 2002; Zald *et al*, 2004), and eating a meal (Small *et al*, 2003). In addition, DA concentration has been found to decrease in subjects who experience decreased happiness/euphoria in response to catecholamine depletion (Verhoeff *et al*, 2003). The present findings reinforce the previously demonstrated relationship between DA concentration and mood, and point to the consistency of these findings across rewarding stimuli.

The strengths of the present study included a relatively large sample size for this line of research; well-matched groups with regard to demographic variables, cigarette usage, and absence of comorbidity; and a statistical method that minimized type I error by using a single BP value. The primary limitations of this study were the ones inherent to PET scanning with ^{11}C -raclopride. Although this radiotracer is commonly used for the evaluation of DA release (Volkow *et al*, 1994; Carson *et al*, 1997; Schlaepfer *et al*, 1997; Ginovart *et al*, 2002; Brody *et al*, 2004, 2006; Marenco *et al*, 2004; Barrett *et al*, 2004; Scott *et al*, 2007) and generally demonstrates DA release when expected, the short half-life and variable pharmacokinetics of the radiotracer make its use logistically challenging for human studies, and can produce considerable variability within groups, as observed here (Figure 1). ^{11}C -raclopride is also not a reliable radiotracer for examining competitive displacement in regions with low specific binding outside the striatum. For measuring non-striatal DA receptor levels, a radiotracer with very high affinity (such as ^{18}F -fallypride) might be more appropriate (for reviews see Siessmeier *et al* (2005); Elsinga *et al* (2006)). Another study limitation was the unequal sample size between the two groups (done for practical reasons), which resulted in greater power to detect change in the larger regular cigarette group compared to the smaller denicotinized cigarette group. Also, due to the fact that de-identified cigarettes of the subjects' own brand were used in this study, it is possible that varying cigarette composition (eg, regular cigarettes smoked here contained 14.2 ± 0.5 mg tar, whereas Quest cigarettes contained 10 mg tar) or the fact that some subjects may have recognized their own brand of cigarettes could have affected study results.

Despite these limitations, this study did demonstrate that smoking regular nicotine cigarettes resulted in VCD/NAC BP change in the hypothesized direction, and this fact does lend confidence to the findings here, as does the expected significant correlation for the total group between VCD/NAC BP reduction and mood improvement.

ACKNOWLEDGEMENTS

This study was supported by the Tobacco-Related Disease Research Program (ALB (11RT-0024 and 16RT-0098), the National Institute on Drug Abuse (ALB (R01s DA15059 and DA20872)), the Veterans Administration (ALB (Merit Review Type I Award)), the National Alliance for Research on Schizophrenia and Depression (ALB), and the Office of National Drug Control Policy (EDL (DABT63-00-C-1003)). We thank Josephine Ribe and Michael Clark for technical support in performing positron emission tomography and magnetic resonance imaging scans, respectively.

CONFLICT OF INTEREST

The author(s) declare that, except for income received from my primary employer, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

REFERENCES

- Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004). The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [(11C)raclopride]. *Synapse* 54: 65–71.
- Benwell ME, Balfour DJ (1997). Regional variation in the effects of nicotine on catecholamine overflow in rat brain. *Eur J Pharmacol* 325: 13–20.
- Bowen R, Baetz M, Hawkes J, Bowen A (2006). Mood variability in anxiety disorders. *J Affect Disord* 91: 165–170.
- Brody AL (2006). Functional brain imaging of tobacco use and dependence. *J Psychiatr Res* 40: 404–418.
- Brody AL, Mandelkern MA, London ED, Childress AR, Bota RG, Ho ML *et al* (2002). Brain metabolic changes during cigarette craving. *Arch Gen Psychiatry* 59: 1162–1172.
- Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S *et al* (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. *Arch Gen Psychiatry* 63: 808–816.
- Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P *et al* (2004). Smoking-induced ventral striatal dopamine release. *Am J Psychiatry* 161: 1211–1218.
- Buchhalter AR, Acosta MC, Evans SE, Breland AB, Eissenberg T (2005). Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. *Addiction* 100: 550–559.
- Buchhalter AR, Schrinel L, Eissenberg T (2001). Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes. *Nicotine Tob Res* 3: 111–118.
- Buckley TC, Holohan DR, Mozley SL, Walsh K, Kassel J (2007). The effect of nicotine and attention allocation on physiological and

- self-report measures of induced anxiety in PTSD: a double-blind placebo-controlled trial. *Exp Clin Psychopharmacol* 15: 154–164.
- Butschky MF, Bailey D, Henningfield JE, Pickworth WB (1995). Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. *Pharmacol Biochem Behav* 50: 91–96.
- Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B et al (1997). Quantification of amphetamine-induced changes in [¹¹C]raclopride binding with continuous infusion. *J Cereb Blood Flow Metab* 17: 437–447.
- Christian BT, Narayanan TK, Shi B, Mukherjee J (2000). Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [(18)F]fallypride in nonhuman primates. *Synapse* 38: 71–79.
- Corrigall WA, Franklin KB, Coen KM, Clarke PB (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. *Psychopharmacology (Berl)* 107: 285–289.
- Cumming P, Rosa-Neto P, Watanabe H, Smith D, Bender D, Clarke PBS et al (2003). Effects of acute nicotine on hemodynamics and binding of [C-11]raclopride to dopamine D-2/D-3 receptors in pig brain. *Neuroimage* 19: 1127–1136.
- Dallery J, Houtsmuller EJ, Pickworth WB, Stitzer ML (2003). Effects of cigarette nicotine content and smoking pace on subsequent craving and smoking. *Psychopharmacology (Berl)* 165: 172–180.
- Damsma G, Day J, Fibiger HC (1989). Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. *Eur J Pharmacol* 168: 363–368.
- Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CRJ (1999). A pharmacologic strategy for the treatment of nicotine addiction. *Synapse* 31: 76–86.
- Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci USA* 85: 5274–5278.
- Donny EC, Houtsmuller E, Stitzer ML (2007). Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. *Addiction* 102: 324–334.
- Drevets WC, Gautier C, Price JC, Kinahan PE, Grace AA et al (2001). Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. *Biol Psychiatry* 49: 81–96.
- Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D et al (1999). PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. *Neuropsychopharmacology* 21: 694–709.
- Ehrin E, Gawell L, Hogberg T, Depaulis T, Strom P (1987). Synthesis of [Methoxy-H-3]- and [Methoxy-C-11]-labeled raclopride—specific dopamine-D2 receptor ligands. *J Labelled Comp Radiopharm* 24: 931–940.
- Eid NC, Fant RV, Moolchan ET, Pickworth WB (2005). Placebo cigarettes in a spaced smoking paradigm. *Pharmacol Biochem Behav* 81: 158–164.
- Elsinga PH, Hatano K, Ishiwata K (2006). PET tracers for imaging of the dopaminergic system. *Curr Med Chem* 13: 2139–2153.
- Fagerström KO (1978). Measuring the degree of physical dependence to tobacco smoking with reference to individualization of treatment. *Addict Behav* 3: 235–241.
- Farde L, Hall H, Ehrin E, Sedvall G (1986). Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. *Science* 231: 258–261.
- First MB, Spitzer RL, Gibbon M, Williams JBW (1995). *Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition (SCID-I/P, version 2.0)*. American Psychiatric Press, Washington, DC.
- Ginovart N, Hassoun W, Le Cavorsin M, Veyre L, Le Bars D, Leviel V (2002). Effects of amphetamine and evoked dopamine release on [C-11]raclopride binding in anesthetized cats. *Neuropsychopharmacology* 27: 72–84.
- Green CR, Rodgman A (1996). The Tobacco Chemists' Research Conference; a half-century of advances in analytical methodology of tobacco and its products. *Recent Advances in Tobacco Science* 22: 131–304.
- Gross J, Lee J, Stitzer ML (1997). Nicotine-containing versus de-nicotinized cigarettes: effects on craving and withdrawal. *Pharmacol Biochem Behav* 57: 159–165.
- Hamilton M (1967). Development of a rating scale for primary depressive illness. *Br J Soc Psychology* 6: 278–296.
- Hamilton M (1969). Diagnosis and rating of anxiety. *Br J Psychiatry* 3: 76–79.
- Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P et al (1997). Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. *J Neural Transm* 104: 329–339.
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991). The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict* 86: 1119–1127.
- Imperato A, Mulas A, Di Chiara G (1986). Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. *Eur J Pharmacol* 132: 337–338.
- Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998). Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [¹¹C]raclopride binding. *J Cereb Blood Flow Metab* 18: 941–950.
- Janhunen S, Ahtee L (2004). Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. *Eur J Pharmacol* 494: 167–177.
- Jarvik ME, Caskey NH, Rose JE, Herskovic JE, Sadeghpour M (1989). Anxiolytic effects of smoking associated with four stressors. *Addict Behav* 14: 379–386.
- Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL (2000). Nicotine blood levels and subjective craving for cigarettes. *Pharmacol Biochem Behav* 66: 553–558.
- Kaasinen V, Vilkmann H, Hietala J, Nagren K, Helenius H, Olsson H et al (2000). Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. *Neurobiol Aging* 21: 683–688.
- Kassel JD, Shiffman S (1997). Attentional mediation of cigarette smoking's effect on anxiety. *Health Psychol* 16: 359–368.
- Koob GF (1992). Drugs of abuse: anatomy, pharmacology and function of reward pathways. *Trends Pharmacol Sci* 13: 177–184.
- Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. *Neuroimage* 4: 153–158.
- Leshner AI, Koob GF (1999). Drugs of abuse and the brain. *Proc Assoc Am Phys* 111: 99–108.
- Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004). Nicotine-induced dopamine release in primates measured with [C-11]raclopride PET. *Neuropsychopharmacology* 29: 259–268.
- Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. *J Cereb Blood Flow Metab* 23: 285–300.
- Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al (2001). Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. *J Cereb Blood Flow Metab* 21: 1034–1057.
- Mitterschiffthaler MT, Fu CH, Dalton JA, Andrew CM, Williams SC (2007). A functional MRI study of happy and sad affective states induced by classical music. *Hum Brain Mapp* 28: 1150–1162.
- Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM (2007). The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. *Synapse* 61: 637–645.
- Naqvi NH, Bechara A (2005). The airway sensory impact of nicotine contributes to the conditioned reinforcing effects of

- individual puffs from cigarettes. *Pharmacol Biochem Behav* **81**: 821–829.
- Naqvi NH, Bechara A (2006). Skin conductance responses are elicited by the airway sensory effects of puffs from cigarettes. *Int J Psychophysiol* **61**: 77–86.
- Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L et al (2005). Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. *Neuropsychopharmacology* **30**: 821–832.
- Pappata S, Dehaene S, Poline JB, Gregoire MC, Jobert A, Delforge J et al (2002). In vivo detection of striatal dopamine release during reward: a PET study with [(11)C]raclopride and a single dynamic scan approach. *Neuroimage* **16**: 1015–1027.
- Park MH, Park EH (2000). Synaptic concentration of dopamine in rat striatal slices in relationship to [³H]raclopride binding to the dopamine D2 receptor. *Arch Pharm Res* **23**: 360–366.
- Pickworth WB, Fant RV, Nelson RA, Rohrer MS (1999). Pharmacodynamic effects of new de-nicotinized cigarettes. *Nicotine Tob Res* **1**: 357–364.
- Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J (1998). Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. *Am J Psychiatry* **155**: 768–773.
- Pomerleau OF, Turk DC, Fertig JB (1984). The effects of cigarette smoking on pain and anxiety. *Addict Behav* **9**: 265–271.
- Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. *Nature* **382**: 255–257.
- Rose JE, Behm FM, Salley AN, Bates JE, Coleman RE, Hawk TC et al (2007). Regional brain activity correlates of nicotine dependence. *Neuropsychopharmacology* **32**: 2441–2452.
- Rose JE, Behm FM, Westman EC, Mathew RJ, London ED, Hawk TC et al (2003). PET studies of the influences of nicotine on neural systems in cigarette smokers. *Am J Psychiatry* **160**: 323–333.
- Schlaepfer TE, Pearlson GD, Wong DF, Marengo S, Dannals RF (1997). PET study of competition between intravenous cocaine and [¹¹C]raclopride at dopamine receptors in human subjects. *Am J Psychiatry* **154**: 1209–1213.
- Schuh KJ, Stitzer ML (1995). Desire to smoke during spaced smoking intervals. *Psychopharmacology (Berl)* **120**: 289–295.
- Schuh LM, Stamat HM, Downey KK, Schuh KJ (2001). Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields. *Nicotine Tob Res* **3**: 77–83.
- Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S et al (2007). Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. *Neuropsychopharmacology* **32**: 450–457.
- Shiffman SM, Jarvik ME (1976). Smoking withdrawal symptoms in two weeks of abstinence. *Psychopharmacology (Berl)* **50**: 35–39.
- Siessmeier T, Zhou Y, Buchholz HG, Landvogt C, Vernaleken I, Piel M et al (2005). Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. *J Nucl Med* **46**: 964–972.
- Slifstein M, Narendran R, Hwang DR, Sudo Y, Talbot PS, Huang Y et al (2004). Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. *Synapse* **54**: 46–63.
- Small DM, Jones-Gotman M, Dagher A (2003). Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. *Neuroimage* **19**: 1709–1715.
- Spielberger C (1983). *Manual for the State-Trait Anxiety Inventory*. Consulting Psychologists Press: Palo Alto, CA.
- Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP et al (2001). Sex differences in [¹²³I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. *Synapse* **41**: 275–284.
- Sziraki I, Lipovac MN, Hashim A, Sershen H, Allen D, Cooper T et al (2001). Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. *Neurochem Res* **26**: 609–617.
- Takahashi H, Fujimura Y, Hayashi M, Takano H, Kato M, Okubo Y et al (2008). Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. *Int J Neuropsychopharmacol* **11**: 413–417.
- Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF (2002). Comparative effects of methamphetamine and nicotine on the striatal [C-11]raclopride binding in unanesthetized monkeys. *Synapse* **45**: 207–212.
- Verhoeff NP, Christensen BK, Hussey D, Lee M, Papatheodorou G, Kopala L et al (2003). Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. *Pharmacol Biochem Behav* **74**: 425–432.
- Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J et al (1999). Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. *Synapse* **31**: 59–66.
- Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R et al (1994). Imaging endogenous dopamine competition with [¹¹C]raclopride in the human brain. *Synapse* **16**: 255–262.
- Wang GJ, Volkow ND, Logan J, Fowler JS, Schlyer D, MacGregor RR et al (1995). Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. *Life Sci* **56**: 249–253.
- Watabe H, Endres CJ, Breier A, Schmall B, Eckelman WC, Carson RE (2000). Measurement of dopamine release with continuous infusion of [¹¹C]raclopride: optimization and signal-to-noise considerations. *J Nucl Med* **41**: 522–530.
- Wild B, Erb M, Bartels M (2001). Are emotions contagious? Evoked emotions while viewing emotionally expressive faces: quality, quantity, time course and gender differences. *Psychiatry Res* **102**: 109–124.
- Woods RP, Mazziotta JC, Cherry SR (1993). MRI-PET registration with automated algorithm. *J Comput Assist Tomogr* **17**: 536–546.
- Zald DH, Boileau I, El-Dearedy W, Gunn R, McGlone F, Dichter GS et al (2004). Dopamine transmission in the human striatum during monetary reward tasks. *J Neurosci* **24**: 4105–4112.
- Zubieta JK, Heitzeg MM, Xu Y, Koeppe RA, Ni L, Guthrie S et al (2005). Regional cerebral blood flow responses to smoking in tobacco smokers after overnight abstinence. *Am J Psychiatry* **162**: 567–577.